Hosted on MSN2mon
Azvudine beats paxlovid in reducing COVID-19 deathsA large-scale study reveals azvudine’s comparable efficacy to Paxlovid, fewer adverse effects, and potential antitumor benefits in patients with liver cancer. Study: Real‐world effectiveness ...
TASS/. The Health Insurance Administration of South China's Hainan Province has temporarily included the country's oral anti-Covid drug Azvudine into the list of medicine covered by medical insurance.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results